ViaCyte Encapsulation Trial
What is encapsulation therapy?
Among the promising paths to a cure is the beta cell encapsulation, one of the pillars of JDRF’s replacement research strategy. It aims to create an unlimited supply of insulin-producing cells, transplant them into the human body safely while providing the necessary protection to allow them to survive the autoimmune attack.
What is the ViaCyte clinical trial about?
After several years of research and efforts, JDRF’s encapsulation project, in collaboration with ViaCyte in San Diego, USA, has now reached a new key milestone with the launch of a second site for clinical trials in Edmonton, Alberta. First of its kind in Canada, this clinical trial will be led by Dr. James Shapiro and his team who is renowned for having developed the Edmonton Protocol, which has targeted the islet transplant as a replacement avenue to remove the burden of multiple daily insulin injections from the lives of people with type 1 diabetes (T1D). The purpose of this research study is to assess the safety, tolerability, and effectiveness of a new delivery system as well as the stem cells.
How do I qualify for the study?
You may be eligible for this study if you are an adult (between the ages of 18 and 55 years old), have been diagnosed with type 1 diabetes mellitus for a minimum of 3 years, and have a stable, optimized diabetic regimen for at least 3 months. Only men and women of non-childbearing potential are eligible for this study. Because the study requires many visits to the clinic, Canadian subjects living in the Edmonton area would be most likely to successfully participate.
For complete details and requirements, download the Letter of Interest and Patient Information Sheet.
Andrew Malcolm, PhD (Immunology)
Operations Director-Research Clinical Islet Transplant Program
University of Alberta